Trending at Lumira Ventures

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Alyssia Watkin Portfolio News, COUR Pharmaceuticals, Main Page

CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) — COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced the closing of a Series A investment round, …